Genentech’s Strategic Pivot: The Closure of Its Cancer Immunology Unit
Introduction In a significant and somewhat unexpected move within the biotech industry, Genentech, a subsidiary of Roche, has…
Breakthrough in Alzheimer’s Treatment: Biogen and Eisai’s Leqembi Wins UK Approval
Introduction The landscape of Alzheimer’s disease treatment has undergone a monumental shift with the UK’s Medicines and Healthcare…
Vera Therapeutics’ Atacicept Shows Promising Results in Phase 2b ORIGIN Trial for IgA Nephropathy
Vera Therapeutics has announced positive results from their Phase 2b ORIGIN clinical trial for atacicept, a novel investigational…
Ozempic Shows Lower Risk of Kidney and Heart Complications in Diabetic Patients
In a groundbreaking development, Novo Nordisk’s Ozempic (semaglutide) has demonstrated significant benefits in reducing the risk of kidney…
Eli Lilly Announces Historic $5.3 Billion Investment to Expand Indiana Manufacturing for Diabetes and Weight Loss Drugs
Expansion to Create 900 Permanent Jobs and Meet Rising Demand for Mounjaro and Zepbound Eli Lilly and Company…
Guardant Health’s Shield Blood Test for Colorectal Cancer Receives FDA Advisory Panel Endorsement
Guardant Health, a prominent player in precision oncology, has taken a significant step forward with its Shield blood…
Coherus Presents Promising Phase I Results for Anti-CCR8 Antibody CHS-114 at ASCO 2024
Coherus BioSciences has announced preliminary results from its Phase I dose-escalation study of CHS-114, an anti-CCR8 antibody, at…
Myriad Genetics Unveils Groundbreaking Cancer Care Innovations at ASCO 2024
Myriad Genetics has once again solidified its position at the forefront of precision medicine and genetic testing with…
Biogen Expands Immunology Portfolio with Strategic Acquisition
Biogen Inc. has announced the acquisition of Human Immunology Biosciences (HI-Bio) for an upfront payment of $1.15 billion,…
Takeda Inks Licensing Deal with Degron Therapeutics for Molecular Glue Degraders
Takeda Pharmaceuticals has announced an exclusive licensing agreement with Degron Therapeutics, a Chinese biotech company, to develop novel…
FDA Approves Biosimilars Yesafili and Opuviz, Opening New Avenues for Affordable Eye Treatments
The FDA has recently approved two new biosimilars, Yesafili (aflibercept-jbvf) by Biocon Biologics and Opuviz (aflibercept-yszy) by Samsung…
Oak Hill Bio and Chiesi Resume Phase 2b Clinical Study for OHB-607 to Treat Bronchopulmonary Dysplasia
Oak Hill Bio and Chiesi Group have announced the enrollment of the first patient in a resumed Phase…
FDA Delays Moderna RSV Vaccine Decision
Moderna’s RSV vaccine, mRNA-1345, has experienced a delay in FDA approval, initially expected by May 12 but now…
Novavax Announces Robust First Quarter 2024 Results and Strategic Partnerships
Novavax (NASDAQ: NVAX), a leader in vaccine innovation, today reported substantial progress in its financial and operational goals…
Novavax and Sanofi Forge $1.2 Billion Alliance to Boost COVID and Flu Vaccine Efforts
In a landmark agreement, Novavax (NASDAQ: NVAX) has partnered with French pharmaceutical giant Sanofi to escalate the fight…
CEL-SCI Advances in Cancer Treatment with FDA Approval for Confirmatory Multikine Study
In a landmark decision, the U.S. Food and Drug Administration (FDA) has green-lighted CEL-SCI Corporation (NYSE American: CVM)…
BIOQUAL Reports Positive Q3 Growth Following Year of Steady Performance
BIOQUAL (OTC Pink: BIOQ) is a company noted for its contributions to health science research. The company’s most…
Petros Pharmaceuticals Advances STENDRA OTC Bid with Positive FDA Feedback
Petros Pharmaceuticals, Inc. has taken a significant step toward making its erectile dysfunction drug, STENDRA, available over-the-counter (OTC),…